Comparing the IOP-Lowering Efficacy of Bimatoprost and Latanoprost Within Separate Glaucoma or Ocular Hypertension Patient Subsets

Abstract

Abstract: : Purpose: To determine the relative IOP-lowering efficacy of bimatoprost 0.03% and latanoprost 0.005% in patient subgroups defined according to baseline diagnosis: ocular hypertension (OHT) or glaucoma. Methods: Multicenter, investigator-masked, 6-month randomized clinical trial. After glaucoma medications were washed out, patients with OHT or glaucoma were randomly assigned to bimatoprost 0.03% (n = 133) or latanoprost 0.005% (n = 136), once daily. The primary outcome measure was mean change from baseline IOP at 8 AM, 12 PM, and 4 PM. A subset analysis was performed to look at efficacy in patients with a baseline diagnosis of OHT or glaucoma. Results: Month 6 results: in OHT patients (n = 93/269), mean reductions from baseline IOP were 1.4 to 2.2 mm Hg greater with bimatoprost than with latanoprost (8 AM: P = .025; 12 PM: P = .002; 4 PM: P = .070). In glaucoma patients (n = 176/269), mean reductions from baseline IOP were 1.3 to 2.2 mm Hg greater with bimatoprost than with latanoprost throughout the day (8 AM: P = .003; 12 PM: P<.001; 4 PM: P = .012). To provide comparability to the Ocular Hypertension Treatment Study, we determined the percentage of patients who achieved at least a 20% reduction from baseline IOP. Significantly more bimatoprost-treated than latanoprost-treated OHT patients achieved at least a 20% reduction in IOP from baseline at each measurement (8 AM: P = .015; 12 PM: P = .005; 4 PM: P = .022). A greater percentage of bimatoprost-treated than latanoprost-treated glaucoma patients also achieved at least a 20% reduction in IOP from baseline (8 AM: P = .076; 12 PM: P = .013; 4 PM: P = .031). Conclusions: Both OHT and glaucoma patients experienced superior IOP-lowering efficacy with bimatoprost than latanoprost at each measurement and each visit.

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: tre